尼达尼布治疗难治性转移性结直肠癌的III期随机对照研究
LUME-Colon 1研究纳入768例标准治疗失败的转移性结直肠癌患者,随机接受尼达尼布或安慰剂。尼达尼布未改善总生存期,虽显著但仅轻度延长无进展生存期,未达到两个共同主要终点。
要点
- 尼达尼布组中位总生存期6.4个月,安慰剂组6.0个月,无显著改善。
- 尼达尼布组中位无进展生存期1.5个月,安慰剂组1.4个月,差异显著但幅度小。
- 两组均无完全或部分缓解,≥3级不良事件以肝脏相关事件和乏力常见。
核心结论
- 研究未达到总生存期和无进展生存期两个共同主要终点,尼达尼布未改善总生存期。
- 尼达尼布较安慰剂显著但仅轻度延长无进展生存期,且耐受性良好。
研究设计与样本
- 全球、随机、双盲、安慰剂对照的III期研究,纳入768例组织学/细胞学确诊的转移性或局部晚期结直肠腺癌患者。
- 患者按1:1随机接受尼达尼布200 mg每日两次或安慰剂每日两次,直至疾病进展或不可耐受毒性。
- 按既往瑞戈非尼使用、转移性疾病起病至随机化时间和地区进行分层。
主要发现
- 尼达尼布组中位总生存期6.4个月,安慰剂组6.0个月,HR 1.01(95%CI 0.86-1.19,P=0.8659)。
- 尼达尼布组中位无进展生存期1.5个月,安慰剂组1.4个月,HR 0.58(95%CI 0.49-0.69,P<0.0001)。
- 两组均无完全或部分缓解。
- 尼达尼布组97%患者发生不良事件,安慰剂组93%;≥3级肝脏相关不良事件发生率分别为16%和8%,乏力分别为9%和6%。
关键数值与推荐
- 共同主要终点为总生存期和中心评估的无进展生存期。
- 次要终点包括中心评估的客观肿瘤缓解和疾病控制。
临床怎么用
- 尼达尼布不推荐用于标准治疗失败的转移性结直肠癌患者常规治疗,因未改善总生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. This global, randomized, phase III study investigated the efficacy and safety of nintedanib in patients with refractory CRC after failure of standard therapies. PATIENTS AND METHODS: Eligible patients (Eastern Cooperative Oncology Group performance status 0-1, with histologically/cytologically confirmed metastatic/locally advanced CRC adenocarcinoma unamenable to surgery and/or radiotherapy) were randomized 1 : 1 to receive nintedanib (200 mg twice daily) or placebo (twice daily), until disease progression or undue toxicity. Patients were stratified by previous regorafenib, time from onset of metastatic disease to randomization, and region. Co-primary end points were overall survival (OS) and progression-free survival (PFS) by central review. Secondary end points included objective tumor response and disease control by central review. RESULTS: From October 2014 to January 2016, 768 patients were randomized; 765 were treated (nintedanib n = 384; placebo n = 381). Median follow-up was 13.4 months (interquartile range 11.1-15.7). OS was not improved [median OS 6.4 months with nintedanib versus 6.0 months with placebo; hazard ratio (HR), 1.01; 95% confidence interval (CI), 0.86-1.19; P = 0.8659]. There was a significant but modest increase in PFS with nintedanib versus placebo (median PFS 1.5 versus 1.4 months, respectively; HR 0.58; 95% CI 0.49-0.69; P < 0.0001). There were no complete or partial responses. Adverse events (AEs) occurred in 97% of 384 nintedanib-treated patients and 93% of 381 placebo-treated patients. The most frequent grade ≥3 AEs were liver-related AEs (nintedanib 16%; placebo 8%) and fatigue (nintedanib 9%; placebo 6%). CONCLUSIONS: The study failed to meet both co-primary end points. Nintedanib did not improve OS and was associated with a significant but modest increase in PFS versus placebo. Nintedanib was well tolerated. CLINICALTRIALS.GOV NUMBER: NCT02149108 (LUME-Colon 1).
引用
- Van Cutsem E, Yoshino T, Lenz HJ, et al. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Ann Oncol. 2018. PMID: 30010751. doi:10.1093/annonc/mdy241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。